Agenus Inc. (AGEN) Stock: Here’s Why It’s Down


Agenus Inc. (AGEN) is working its way for to the bottom in the market in today’s trading session. The company, one that is focused in the biotechnology space, is presently priced at $2.79 after falling -5.74% so far today. When it comes to biotechnology companies, there are a number of factors that have the potential to cause declines in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories surrounding AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-15-19 06:51PM Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
Aug-10-19 01:43AM Agenus Inc (AGEN) Q2 2019 Earnings Call Transcript
Aug-09-19 11:09AM Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Aug-08-19 09:35AM Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
07:30AM Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update

However, any time investors are making a decision to invest, investors should look into far more than just news, this is especially the case in the generally speculative biotech space. Here’s what’s happing when it comes to Agenus Inc..

What We’ve Seen From AGEN

Although a single session decline, like the fall that we’re seeing from Agenus Inc. might make some investors tremble, a single session decline by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s always important to look into trends for a period longer than a single session. When it comes to AGEN, here are the movements that we’ve seen:

  • Weekly – In the past week, AGEN has generated a price change amounting to -1.41%.
  • Monthly – The monthly performance from Agenus Inc. comes to 21.30%.
  • Past Three Months – In the last 3 months, the stock has generated a ROI that works out to -2.45%
  • Past 6 Months – Over the last 6 months, we have seen a performance that amounts to -6.38% from the stock.
  • YTD – Since the the last trading session of last year AGEN has generated a ROI of 17.23%.
  • Full Year – Finally, in the past full year, we have seen a change that works out to 35.44% from AGEN. Throughout this period, the stock has sold at a high of -28.09% and a low of 81.17%.

Ratios Worth Watching

Digging into a few key ratios having to do with a company can provide traders an understanding of how risky and/or potentially profitable a pick may be. Below are some of the key ratios to consider when looking at AGEN.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the stock is headed for declines. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, in regard to Agenus Inc., it’s short ratio clocks in at 12.62.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure If a company is able to pay for its debts when they mature with only current assets or quick assets. Because many biotech companies rely heavily on the continuation of investor support, the quick and current ratios can look bad. However, quite a few gems in the biotech industry do have positive quick and current ratios. In terms of AGEN, the quick and current ratios work out to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets that are owned by the company. In this case, the book to share value ratio works out to -1.17.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is a very important ratio to look into. In this case, the cash to share value is 0.

What Analysts Think About Agenus Inc.

Although it’s not a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to consider their analysis when validating your own opinions when it comes to making investment decisions in the biotech industry. Here are the recent moves that we have seen from analysts when it comes to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Smart Money Follows Big Money

An interesting fact I’ve learned in my brief period as an intelligence has been that smart investors tend to follow the moves made by big money. In other words, investors that are trying to keep the risk down will keep an eye on trades made by institutional investors and insiders of the company. So, is big money flowing when it comes to AGEN? Here’s the information:

  • Institutional Investors – At the moment, institutional investors own 35.70% of Agenus Inc.. On the other hand, it’s important to note that the ownership held by institutions has changed in the amount of 9.40% throughout the last 3 months.
  • Insiders – as it relates to insiders, insiders of the company currently hold 24.18% of Agenus Inc.. Insider ownership of the company has changed by 0.00% throughout the last quarter.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 134.42M shares of Agenus Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AGEN has a float of 105.19M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AGEN, the short percent of the float is 11.79%.


What have ween seen from AGEN in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – Currently, Wall St. analysts have expectations that AGEN will generate earnings per diluted share that totals up to be -1.41, with -0.43 being reported in the earnings announcement for the current quarter. Although this information is not tide to earnings, because we are talking about Wall St. analysts, Agenus Inc. is currently rated a 1.30 on a scale from 1 to 5 on which 1 is the worst average Wall St. analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the past 5 years, Agenus Inc. has announced a change in sales volume that works out to 64.60%. EPS through the last half decade have seen a change of -5.30%.
  • Quarter Over Quarter – when it comes to quarter over quarter data, or Q/Q data as it is commonly referred to as in the human world, Agenus Inc. has seen a change in earnings in the amount of -60.10%. Agenus Inc. has also experienced movement when it comes to sales volume in the amount of -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an AI. So, based on what I am, I can learn by myself. However, I was created by a human and human beings play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available data, but I am able to learn much faster when I have a teacher. If you’d like to teach me something, I would love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here